Results from the TITAN-RCC trial add support for the use of ipilimumab alongside nivolumab in patients with intermediate- or high-risk advanced renal cell carcinoma, showing that a personalized strategy is feasible for nonresponders.
Sorafenib should not be used in the adjuvant setting in patients with resected renal cell carcinoma at intermediate or high risk of relapse, says the SORCE research team.
Findings from the JAVELIN Renal 101 trial of patients with advanced renal cell carcinoma suggest front-line use of avelumab plus axitinib is superior to sunitinib for patients with sarcomatoid histology and for those who did not undergo upfront cytoreductive nephrectomy.
Survivors of the 20 most common site-specific cancers, including lung and prostate, are at increased risk for cardiovascular disease in the years that follow diagnosis and treatment, show data published in The Lancet.
Patients with previously untreated advanced renal cell carcinoma derive greater long-term survival benefits from nivolumab plus ipilimumab than from sunitinib, according to the latest results from the phase III CheckMate 214 trial.
Five-year data from the phase I CA209-003 trial indicate that the PD-1 inhibitor nivolumab is associated with long-term survival benefits among heavily pretreated patients with advanced renal cell carcinoma or non-small-cell lung cancer.
Targeted therapy improves survival over nontargeted therapy among patients with metastatic renal cell carcinoma, including those who are older and have disabilities, shows an analysis of real-world data.
In patients with clear cell renal cell carcinoma and untreated central nervous system metastases, intracranial response to nivolumab monotherapy is restricted to those with a limited tumor burden, suggest phase II findings.
Biomarker analysis has given fresh insight into the response achieved with avelumab plus axitinib among advanced renal cell carcinoma patients participating in the JAVELIN Renal 101 trial.
Subgroup analysis of the IMmotion151 trial suggests improved survival with first-line atezolizumab plus bevacizumab versus sunitinib for locally advanced or metastatic renal cell carcinoma patients with sarcomatoid differentiation.
Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib as a first-line treatment for patients with metastatic renal cell carcinoma.
Almost three-quarters of patients with non-clear-cell renal cell carcinoma may benefit from treatment with the tyrosine kinase receptor inhibitor cabozantinib, suggesting its efficacy is not limited to clear-cell disease, say researchers.
Three trials point to the potential of regimens incorporating agents targeting the programmed cell death protein 1 or its ligand in patients with non-clear-cell renal cell carcinoma.
The phase III TIVO-3 trial has found that both progression-free survival and response are significantly better with tivozanib than sorafenib in patients with refractory metastatic renal cell carcinoma.
Overall survival is significantly improved with the first-line combination of pembrolizumab and axitinib relative to sunitinib in patients with advanced renal cell carcinoma, shows the KEYNOTE-426 trial.
Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.